Combination therapy for treatment of cancer
AssigneeOncoMed Pharmaceuticals, Inc.
InventorsAustin L. GURNEY, Wan-Ching YEN
Life of this patent
Estimating the term…
Abstract
The present invention provides methods comprising combination therapy for treating cancer. Wnt pathway inhibitors in combination with mitotic inhibitors administered in a staggered or sequential dosing manner for the treatment of cancer and other diseases.
Claims68
A method of treating cancer comprising:
- administering to a subject a therapeutically effective amount of a Wnt pathway inhibitor and a therapeutically effective amount of a mitotic inhibitor, wherein the Wnt pathway inhibitor and the mitotic inhibitor are administered using a staggered dosing schedule and the Wnt pathway inhibitor is administered first;
- and wherein the Wnt pathway inhibitor is:
- (a) an antibody that specifically binds at least one human Frizzled (FZD) protein, or
- (b) a soluble receptor comprising the Fri domain of a human FZD protein.
A method of inhibiting tumor growth comprising:
- administering to a subject a therapeutically effective amount of a Wnt pathway inhibitor and a therapeutically effective amount of a mitotic inhibitor, wherein the Wnt pathway inhibitor and the mitotic inhibitor are administered using a staggered dosing schedule and the Wnt pathway inhibitor is administered first;
- and wherein the Wnt pathway inhibitor is:
- (a) an antibody that specifically binds at least one human Frizzled (FZD) protein, or
- (b) a soluble receptor comprising the Fri domain of a human FZD protein.
A method of reducing the size of a tumor in a subject comprising:
- administering to the subject a therapeutically effective amount of a Wnt pathway inhibitor and a therapeutically effective amount of a mitotic inhibitor, wherein the Wnt pathway inhibitor and the mitotic inhibitor are administered using a staggered dosing schedule and the Wnt pathway inhibitor is administered first;
- and wherein the Wnt pathway inhibitor is:
- (a) an antibody that specifically binds at least one human Frizzled (FZD) protein, or
- (b) a soluble receptor comprising the Fri domain of a human FZD protein.
A method of inducing tumor regression in a subject comprising:
- administering to a subject a therapeutically effective amount of a Wnt pathway inhibitor and a therapeutically effective amount of a mitotic inhibitor, wherein the Wnt pathway inhibitor and the mitotic inhibitor are administered using a staggered dosing schedule and the Wnt pathway inhibitor is administered first;
- and wherein the Wnt pathway inhibitor is:
- (a) an antibody that specifically binds at least one human Frizzled (FZD) protein, or
- (b) a soluble receptor comprising the Fri domain of a human FZD protein.
A method of increasing the efficacy of a mitotic inhibitor in treating cancer in a subject comprising:
- administering to the subject a mitotic inhibitor about 1, 2, 3, 4, 5, or 6 days after a Wnt pathway inhibitor is administered, wherein the Wnt pathway inhibitor is:
- (a) an antibody that specifically binds at least one human Frizzled (FZD) protein, or
- (b) a soluble receptor comprising a comprising a Fri domain of a human FZD protein.
A method of increasing the efficacy of a mitotic inhibitor in treating cancer in a subject comprising:
- (a) administering to the subject a Wnt pathway inhibitor, wherein the Wnt pathway inhibitor is:
- (i) an antibody that specifically binds at least one human Frizzled (FZD) protein, or
- (ii) a soluble receptor comprising a Fri domain of a human FZD protein;
- and
- (b) administering to the subject a mitotic inhibitor about 1, 2, 3, 4, 5, or 6 days after the Wnt pathway inhibitor is administered.
A method of increasing the efficacy of a Wnt pathway inhibitor in treating cancer in a subject comprising:
- administering to the subject a mitotic inhibitor about 1, 2, 3, 4, 5, or 6 days after a Wnt pathway inhibitor is administered, wherein the Wnt pathway inhibitor is:
- (a) an antibody that specifically binds at least one human Frizzled (FZD) protein, or
- (b) a soluble receptor comprising a comprising a Fri domain of a human FZD protein.
A method of increasing the efficacy of a Wnt pathway inhibitor in treating cancer in a subject comprising:
- (a) administering to the subject a Wnt pathway inhibitor, wherein the Wnt pathway inhibitor is:
- (i) an antibody that specifically binds at least one human Frizzled (FZD) protein, or
- (ii) a soluble receptor comprising a Fri domain of a human FZD protein;
- and
- (b) administering to the subject a mitotic inhibitor about 1, 2, 3, 4, 5, or 6 days after the Wnt pathway inhibitor is administered.
A method of treating cancer comprising administering to a subject a therapeutically effective amount of vantictumab and a therapeutically effective amount of a taxane selected from the group consisting of paclitaxel, nab-paclitaxel, and docetaxel, wherein the taxane is administered about 1, 2, 3, 4, 5, or 6 days after vantictumab is administered.
A method of treating cancer comprising administering to a subject a therapeutically effective amount of ipafricept and a therapeutically effective amount of a taxane selected from the group consisting of paclitaxel, nab-paclitaxel, and docetaxel, wherein the taxane is administered about 1, 2, 3, 4, 5, or 6 days after ipafricept is administered.
Dependencies are inferred from the claim text.